核酸治疗市场规模、份额和成长分析（按产品、适应症、最终用户和地区）- 产业预测，2025-2032 年

全球核酸治疗市场预计将在 2023 年达到 59 亿美元，并从 2024 年的 67 亿美元成长到 2032 年的 185.9 亿美元，预测期内（2025-2032 年）的复合年增长率为 13.6%。

随着人们对癌症、癫痫、糖尿病、结核病和爱滋病等慢性疾病的创新治疗兴趣日益浓厚，核酸治疗市场可望快速成长。核酸，包括 DNA、RNA 和合成变体，对于向细胞传递基本讯息至关重要，并因其重要的治疗应用而受到认可。随着多种新治疗方法的核准和强劲的开发平臺，市场正在蓬勃发展，这得益于製药和医疗保健领域的进步，尤其是生物製药和 DNA 疗法领域的进步。随着对有效慢性病治疗的需求不断增长，这为相关人员提供了充满希望的机会，使基于核酸的解决方案处于现代医学的前沿。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 宏观经济指标
• 价值链分析
• 定价分析
• 案例研究分析

核酸治疗市场规模（按产品和复合年增长率） (2025-2032)

• 市场概况
• 反义寡核苷酸 (ASO)
• RNA干扰（RNAi）
• RNA适体

核酸治疗药物市场规模（按适应症和复合年增长率） (2025-2032)

• 市场概况
• 自体免疫疾病
• 感染疾病
• 遗传性疾病
• 癌症
• 其他的

核酸治疗市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概况
• 医院
• 诊所
• 其他的

核酸治疗市场规模（依地区划分）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• Wave Life Science Ltd.（Singapore）
• Imugene（Australia）
• Aileron Therapeutics Inc.（US）
• BioNTech SE（Germany）
• Protagonist Therapeutics Inc.（US）
• Replicate Bioscience Inc.（US）
• Eli Lilly and Company（US）
• Copernicus Therapeutics Inc.（US）
• Invio Pharmaceuticals Inc.（US）
• Benitec Biopharma（Australia）
• Alnylam Pharmaceuticals（US）
• Zydus Cadila（India）
• Excision BioTherapeutics（US）
• Pfizer Inc.（US）
• Rhythm Pharmaceuticals Inc.（US）
• Axcella Health Inc.（US）

结论和建议

Global Nucleic Acid Therapeutics Market size was valued at USD 5.9 billion in 2023 and is poised to grow from USD 6.7 billion in 2024 to USD 18.59 billion by 2032, growing at a CAGR of 13.6% during the forecast period (2025-2032).

The nucleic acid therapeutics market is poised for rapid growth, driven by increased interest in innovative treatments for chronic diseases, including cancer, epilepsy, diabetes, tuberculosis, and AIDS. Nucleic acids, encompassing DNA, RNA, and synthetic variants, are pivotal in conveying essential cellular information and are recognized for their critical therapeutic applications. With multiple new therapies gaining approval and a robust pipeline of developments, the market is experiencing an upswing, fueled by advancements in the pharmaceutical and healthcare sectors, particularly within biopharmaceuticals and DNA therapeutics. This landscape showcases a promising opportunity for stakeholders as the demand for effective chronic disease treatments continues to escalate, positioning nucleic acid-based solutions at the forefront of modern medicine.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Nucleic Acid Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Nucleic Acid Therapeutics Market Segmental Analysis

Global Nucleic Acid Therapeutics Market is segmented by Product, Indication, End-user and region. Based on Product, the market is segmented into Anti-Sense Oligonucleotides (ASO), RNA Interference (RNAi) and RNA Aptamers. Based on Indication, the market is segmented into Autoimmune Disorders, Infectious Diseases, Genetic Disorders, Cancer and Others. Based on End-user, the market is segmented into Hospitals, Physicians' Offices and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Nucleic Acid Therapeutics Market

The Global Nucleic Acid Therapeutics market is significantly driven by the rapid advancements in molecular technologies and the extensive research in the field of omics. This evolving landscape has prompted numerous companies to intensify their investments as they strive to enhance their competitive edge. As the market evolves, various business strategies, such as acquisitions, partnerships, and collaborations, play a crucial role in capturing market share and generating revenue. A notable example is Merck & Co.'s announcement in August 2022 regarding a collaborative effort with Orna Therapeutics aimed at discovering, developing, and commercializing innovative RNA-based therapies targeting vaccines, infectious diseases, and oncology.

Restraints in the Global Nucleic Acid Therapeutics Market

The Global Nucleic Acid Therapeutics market faces significant restraints, notably in the area of delivery challenges. A primary obstacle is the effective transport of nucleic acid therapies to their intended target cells, as achieving precise localization while minimizing off-target effects is complex. The intricate nature of nucleic acid compounds often complicates their integration into existing biological systems, leading to potential inefficacies in treatment outcomes. As a result, overcoming these delivery-related issues is crucial for the market's growth, necessitating ongoing research and innovative solutions to enhance the precision and effectiveness of these therapeutic agents in clinical applications.

Market Trends of the Global Nucleic Acid Therapeutics Market

The Global Nucleic Acid Therapeutics market is experiencing significant growth, fueled by heightened investments in healthcare services and a growing focus on advanced treatment methodologies. As the prevalence of genetic disorders and chronic illnesses rises, research and development efforts are intensifying, leading to innovative therapeutic solutions leveraging nucleic acids, such as RNA-based therapies and gene editing techniques. This surge in investment is not only accelerating the pace of research but also enhancing health facility capabilities, thereby expanding market opportunities. Additionally, increased collaboration between public and private sectors is facilitating breakthroughs in treatment, positioning nucleic acid therapeutics as a cornerstone in modern medical care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Study Analysis

Global Nucleic Acid Therapeutics Market Size by Product & CAGR (2025-2032)

• Market Overview
• Anti-Sense Oligonucleotides (ASO)
• RNA Interference (RNAi)
• RNA Aptamers

Global Nucleic Acid Therapeutics Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Autoimmune Disorders
• Infectious Diseases
• Genetic Disorders
• Cancer
• Others

Global Nucleic Acid Therapeutics Market Size by End-user & CAGR (2025-2032)

• Market Overview
• Hospitals
• Physicians' Offices
• Others

Global Nucleic Acid Therapeutics Market Size & CAGR (2025-2032)

• North America (Product, Indication, End-user)
  • US
  • Canada
• Europe (Product, Indication, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Indication, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Indication, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Indication, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Wave Life Science Ltd. (Singapore)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Imugene (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aileron Therapeutics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Protagonist Therapeutics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Replicate Bioscience Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Copernicus Therapeutics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Invio Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Benitec Biopharma (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Excision BioTherapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rhythm Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Axcella Health Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations